

Bruno Sangro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4395983/publications.pdf>

Version: 2024-02-01

257
papers

26,936
citations

9264

74
h-index

6996

154
g-index

268
all docs

268
docs citations

268
times ranked

20431
citing authors

#	ARTICLE	IF	CITATIONS
1	Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 475-485.	2.5	13
2	A Simple Prognostic Scoring System for Hepatocellular Carcinoma Treated with Selective Internal Radiation Therapy. <i>Digestive Diseases</i> , 2022, 40, 322-334.	1.9	3
3	Computational Fluid Dynamics Modeling of Liver Radioembolization: A Review. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 12-20.	2.0	13
4	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. <i>Journal of Hepatology</i> , 2022, 76, 681-693.	3.7	1,495
5	“Computational study of a novel catheter for liver radioembolization”, <i>International Journal for Numerical Methods in Biomedical Engineering</i> , 2022, , e3577.	2.1	2
6	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 77-90.	10.7	526
7	A new animal model of atrophy“hypertrophy complex and liver damage following Yttrium-90 lobar selective internal radiation therapy in rabbits. <i>Scientific Reports</i> , 2022, 12, 1777.	3.3	3
8	Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.. <i>Journal of Clinical Oncology</i> , 2022, 40, 379-379.	1.6	235
9	Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies. <i>Advances in Cancer Research</i> , 2022, , 367-413.	5.0	6
10	Neoantigens as potential vaccines in hepatocellular carcinoma. , 2022, 10, e003978.		16
11	Pure laparoscopic major liver resection after yttrium90 radioembolization: a case-matched series analysis of feasibility and outcomes. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 1099-1111.	1.9	2
12	Monitoring one-carbon metabolism by mass spectrometry to assess liver function and disease. <i>Journal of Physiology and Biochemistry</i> , 2022, 78, 229-243.	3.0	4
13	Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2555-2566.	7.0	31
14	Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 3537-3545.	7.0	52
15	DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis. <i>Cancers</i> , 2022, 14, 2048.	3.7	5
16	Immunotherapy in HCC“No rush despite the hype. <i>Hepatology</i> , 2022, 76, 906-908.	7.3	1
17	Immunotherapy in hepatocellular carcinoma. <i>Revista Espanola De Enfermedades Digestivas</i> , 2022, , .	0.3	1
18	Analysis of the albumin“bilirubin score as an indicator of improved liver function among hepatitis C virus patients with sustained viral response after direct“acting antiviral therapy. <i>JGH Open</i> , 2022, 6, 496-502.	1.6	4

#	ARTICLE	IF	CITATIONS
19	How Could 90Y-Loaded Microsphere Distribution Be Optimized?. CardioVascular and Interventional Radiology, 2022, 45, 970-971.	2.0	1
20	Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.. Journal of Clinical Oncology, 2022, 40, 4074-4074.	1.6	2
21	Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial. Clinical Cancer Research, 2022, 28, 3890-3901.	7.0	14
22	Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT). CardioVascular and Interventional Radiology, 2021, 44, 21-35.	2.0	49
23	Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France. CardioVascular and Interventional Radiology, 2021, 44, 36-49.	2.0	15
24	A proof-of-concept study of the in-vivo validation of a computational fluid dynamics model of personalized radioembolization. Scientific Reports, 2021, 11, 3895.	3.3	12
25	Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. European Journal of Radiology, 2021, 135, 109484.	2.6	20
26	The joint use of 99mTc-MAA-SPECT/CT and cone-beam CT optimizes radioembolization planning. EJNMMI Research, 2021, 11, 23.	2.5	5
27	Long Noncoding RNA EGOT Responds to Stress Signals to Regulate Cell Inflammation and Growth. Journal of Immunology, 2021, 206, 1932-1942.	0.8	6
28	3D voxel-based dosimetry to predict contralateral hypertrophy and an adequate future liver remnant after lobar radioembolization. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3048-3057.	6.4	12
29	Advances in immunotherapy for hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 525-543.	17.8	609
30	CFD Simulations of Radioembolization: A Proof-of-Concept Study on the Impact of the Hepatic Artery Tree Truncation. Mathematics, 2021, 9, 839.	2.2	5
31	The Landscape of lncRNAs in Hepatocellular Carcinoma: A Translational Perspective. Cancers, 2021, 13, 2651.	3.7	18
32	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Medicina Clínica (English Edition), 2021, 156, 463.e1-463.e30.	0.2	16
33	Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Reports, 2021, 3, 100260.	4.9	36
34	Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization. EJNMMI Research, 2021, 11, 51.	2.5	7
35	The splicing regulator SLU7 is required to preserve DNMT1 protein stability and DNA methylation. Nucleic Acids Research, 2021, 49, 8592-8609.	14.5	2
36	Long Noncoding RNA NIHCOLE Promotes Ligation Efficiency of DNA Double-Strand Breaks in Hepatocellular Carcinoma. Cancer Research, 2021, 81, 4910-4925.	0.9	30

#	ARTICLE	IF	CITATIONS
37	Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, 75, 1387-1396.	3.7	22
38	Selective Internal Radiation Therapy Approval for Early HCC: What Comes Next?. <i>Hepatology</i> , 2021, 74, 2333-2335.	7.3	8
39	CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 600-609.	3.7	127
40	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43
41	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2991-3001.	1.6	257
42	Systemic treatment of hepatocellular carcinoma: An EASL position paper. <i>Journal of Hepatology</i> , 2021, 75, 960-974.	3.7	217
43	International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1570-1584.	6.4	140
44	A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC. <i>Hepatology Communications</i> , 2021, 5, 538-547.	4.3	6
45	Immunotherapy for patients with hepatocellular carcinoma and chronic viral infections.. <i>Journal of Hepatology</i> , 2021, , .	3.7	3
46	In Vitro Model for Simulating Drug Delivery during Balloon-Occluded Transarterial Chemoembolization. <i>Biology</i> , 2021, 10, 1341.	2.8	2
47	Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. <i>Hepatology</i> , 2020, 72, 198-212.	7.3	92
48	From the Editor's Desk . <i>Journal of Hepatology</i> , 2020, 72, 1-4.	3.7	1
49	Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib. <i>JAMA Oncology</i> , 2020, 6, e204564.	7.1	746
50	Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, 1460-1469.	3.7	254
51	Reply to: "Toxicity and dosimetry in SORAMIC study". <i>Journal of Hepatology</i> , 2020, 73, 735-736.	3.7	0
52	Lymphocytes, Neutrophils and the Response to Selective Internal Radiation Therapy: More Questions than Answers Yet. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1182-1183.	2.0	1
53	Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3397.	3.7	17
54	Identification of neoantigen-reactive T cells in hepatocellular carcinoma: implication in adoptive T cell therapy. <i>Journal of Hepatology</i> , 2020, 73, S39-S40.	3.7	6

#	ARTICLE	IF	CITATIONS
55	International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis. <i>Liver International</i> , 2020, 40, 1467-1476.	3.9	15
56	The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1165-1172.	2.0	6
57	The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 174-185.	3.8	13
58	On the importance of spiral-flow inflow boundary conditions when using idealized artery geometries in the analysis of liver radioembolization: A parametric study. <i>International Journal for Numerical Methods in Biomedical Engineering</i> , 2020, 36, e3337.	2.1	3
59	Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 320-341.	3.7	165
60	Milestones in the pathogenesis and management of primary liver cancer. <i>Journal of Hepatology</i> , 2020, 72, 209-214.	3.7	39
61	Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4508-4508.	1.6	86
62	Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.. <i>Journal of Clinical Oncology</i> , 2020, 38, 478-478.	1.6	93
63	Liver Radioembolization: An Analysis of Parameters that Influence the Catheter-Based Particle-Delivery via CFD. <i>Current Medicinal Chemistry</i> , 2020, 27, 1600-1615.	2.4	15
64	Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study. <i>JMIR Research Protocols</i> , 2020, 9, e16296.	1.0	8
65	Identification of Coding and Long Noncoding RNAs Differentially Expressed in Tumors and Preferentially Expressed in Healthy Tissues. <i>Cancer Research</i> , 2019, 79, 5167-5180.	0.9	38
66	Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 71, 1164-1174.	3.7	249
67	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. <i>Journal of Hepatology</i> , 2019, 70, 874-884.	3.7	67
68	Splicing events in the control of genome integrity: role of SLU7 and truncated SRSF3 proteins. <i>Nucleic Acids Research</i> , 2019, 47, 3450-3466.	14.5	53
69	Hepatocellular Carcinoma: Essentials Interventional Radiologists Need to Know. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1262-1270.	2.0	2
70	FRI-499-Efficacy and hepatic safety of nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040. <i>Journal of Hepatology</i> , 2019, 70, e619.	3.7	4
71	Medical treatment for cholangiocarcinoma. <i>Liver International</i> , 2019, 39, 123-142.	3.9	69
72	A methodology for numerically analysing the hepatic artery haemodynamics during B-TACE: a proof of concept. <i>Computer Methods in Biomechanics and Biomedical Engineering</i> , 2019, 22, 518-532.	1.6	4

#	ARTICLE	IF	CITATIONS
73	Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 661-668.	6.4	7
74	Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2019, 70, 547-562.	7.3	112
75	Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 379-393.	4.2	100
76	Radioembolisation in Hepatocellular Carcinoma: Principles of Management. , 2019, , 139-152.		2
77	Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4012-4012.	1.6	178
78	Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.. <i>Journal of Clinical Oncology</i> , 2019, 37, 327-327.	1.6	80
79	Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1721-1730.	6.4	18
80	Numerical zero-dimensional hepatic artery hemodynamics model for balloon-occluded transarterial chemoembolization. <i>International Journal for Numerical Methods in Biomedical Engineering</i> , 2018, 34, e2983.	2.1	11
81	Targets for immunotherapy of liver cancer. <i>Journal of Hepatology</i> , 2018, 68, 157-166.	3.7	129
82	Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. <i>Hepatology</i> , 2018, 67, 612-622.	7.3	55
83	Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes. <i>Clinical Cancer Research</i> , 2018, 24, 1518-1524.	7.0	194
84	The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1468-1477.	3.8	72
85	Selective internal radiation therapy: an effective treatment for hormonal syndromes in pancreatic neuroendocrine tumors. <i>Hepatic Oncology</i> , 2018, 5, HEP09.	4.2	2
86	Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7315-7321.	2.0	54
87	Segmental Pneumonitis after Radioembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1305-1306.	0.5	2
88	Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040.. <i>Journal of Clinical Oncology</i> , 2018, 36, 475-475.	1.6	39
89	Pneumatocele during sorafenib therapy: first report of an unusual complication. <i>Oncotarget</i> , 2018, 9, 6652-6656.	1.8	3
90	Deregulation of <i>linc-PINT</i> in acute lymphoblastic leukemia is implicated in abnormal proliferation of leukemic cells. <i>Oncotarget</i> , 2018, 9, 12842-12852.	1.8	43

#	ARTICLE	IF	CITATIONS
91	Phase 1â€“2 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrowâ€“derived endothelial progenitor cells. <i>Translational Research</i> , 2017, 188, 80-91.e2.	5.0	28
92	Computational particleâ€“haemodynamics analysis of liver radioembolization pretreatment as an actual treatment surrogate. <i>International Journal for Numerical Methods in Biomedical Engineering</i> , 2017, 33, e02791.	2.1	19
93	Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. <i>British Journal of Cancer</i> , 2017, 116, 448-454.	6.4	66
94	Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them. <i>Journal of Hepatology</i> , 2017, 66, 1114-1117.	3.7	26
95	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. <i>Lancet, The</i> , 2017, 389, 2492-2502.	13.7	3,224
96	Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review. <i>Hepatology</i> , 2017, 66, 969-982.	7.3	99
97	The role of angledâ€“tip microcatheter and microsphere injection velocity in liver radioembolization: A computational particleâ€“hemodynamics study. <i>International Journal for Numerical Methods in Biomedical Engineering</i> , 2017, 33, e2895.	2.1	15
98	Radioembolization for hepatocellular carcinoma: gaining insight on a personalized approach. <i>Liver International</i> , 2017, 37, 32-34.	3.9	2
99	Immune Checkpoint Inhibitors for the Treatment of Hepatocellular Carcinoma. , 2017, , 51-68.		0
100	Is a Technetium-99m Macroaggregated Albumin Scan Essential in the Workup for Selective Internal Radiation Therapy with Yttrium-90? An Analysis of 532 Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1536-1542.	0.5	19
101	Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases. <i>Future Oncology</i> , 2017, 13, 2065-2082.	2.4	10
102	Totally Laparoscopic Right Hepatectomy for Living Donor Liver Transplantation: Analysis of a Preliminary Experience on 5 Consecutive Cases. <i>Transplantation</i> , 2017, 101, 548-554.	1.0	46
103	Recommendations for radioembolisation after liver surgery using yttrium-90 resin microspheres based on a survey of an international expert panel. <i>European Radiology</i> , 2017, 27, 4923-4930.	4.5	8
104	The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres. <i>Annals of Surgical Oncology</i> , 2017, 24, 2465-2473.	1.5	42
105	Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 1079-1099.	1.4	34
106	Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4013-4013.	1.6	76
107	Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4073-4073.	1.6	133
108	Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation. <i>Annals of Transplantation</i> , 2017, 22, 141-147.	0.9	20

#	ARTICLE	IF	CITATIONS
109	NatB-mediated protein N-terminus acetylation is a potential therapeutic target in hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 40967-40981.	1.8	29
110	Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib. <i>Oncotarget</i> , 2017, 8, 103077-103086.	1.8	41
111	Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2017, , 25-43.	0.1	0
112	Assessment of the Hong Kong Liver Cancer Staging System in Europe. <i>Liver International</i> , 2016, 36, 911-917.	3.9	16
113	Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. <i>British Journal of Cancer</i> , 2016, 114, 744-750.	6.4	150
114	Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. <i>Journal of Hepatology</i> , 2016, 65, 719-726.	3.7	883
115	Computational assessment of the effects of the catheter type on particle hemodynamics during liver radioembolization. <i>Journal of Biomechanics</i> , 2016, 49, 3705-3713.	2.1	17
116	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 511.e1-511.e22.	0.2	2
117	Numerical investigation of liver radioembolization via computational particle hemodynamics: The role of the microcatheter distal direction and microsphere injection point and velocity. <i>Journal of Biomechanics</i> , 2016, 49, 3714-3721.	2.1	12
118	Hepatocellular carcinoma. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16018.	30.5	1,863
119	Factors related to increased resting energy expenditure in men with liver cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 139-145.	1.6	25
120	Liver cancer arterial perfusion modelling and CFD boundary conditions methodology: a case study of the haemodynamics of a patient-specific hepatic artery in literature-based healthy and tumour-bearing liver scenarios. <i>International Journal for Numerical Methods in Biomedical Engineering</i> , 2016, 32, e02764.	2.1	26
121	The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer. , 2016, 4, .		18
122	Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. <i>Journal of Hepatology</i> , 2016, 65, 776-783.	3.7	119
123	A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib. <i>Liver International</i> , 2016, 36, 1206-1212.	3.9	52
124	Agnesis of the dorsal pancreas: systematic review of a clinical challenge. <i>Revista Espanola De Enfermedades Digestivas</i> , 2016, 108, 000-000.	0.3	21
125	Radioembolization as an adjunct therapy to the resection of liver tumors. <i>Hepatic Oncology</i> , 2015, 2, 335-338.	4.2	1
126	Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection. <i>Molecular Therapy - Methods and Clinical Development</i> , 2015, 2, 15006.	4.1	15

#	ARTICLE	IF	CITATIONS
127	Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial <scp>SORAMIC</scp>. Liver International, 2015, 35, 620-626.	3.9	74
128	Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approachâ€”The ALBI Grade. Journal of Clinical Oncology, 2015, 33, 550-558.	1.6	1,810
129	Physiological outflow boundary conditions methodology for small arteries with multiple outlets: A patient-specific hepatic artery haemodynamics case study. Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine, 2015, 229, 291-306.	1.8	11
130	Immune monitoring of immunosuppression withdrawal of liver transplant recipients. Transplant Immunology, 2015, 33, 110-116.	1.2	25
131	Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation. Liver International, 2015, 35, 1590-1596.	3.9	55
132	Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver International, 2015, 35, 1715-1721.	3.9	132
133	Immunological landscape and immunotherapy of hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 681-700.	17.8	478
134	Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.. Journal of Clinical Oncology, 2015, 33, LBA101-LBA101.	1.6	29
135	Transarterial Chemoembolization and Radioembolization. Seminars in Liver Disease, 2014, 34, 435-443.	3.6	71
136	Liver function considerations for post-selective internal radiation therapy resection (hepatocellular) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.4	1
137	Evidence-based integration of selective internal radiation therapy into hepatocellular carcinoma management. Future Oncology, 2014, 10, 7-11.	2.4	1
138	Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins. Clinical Cancer Research, 2014, 20, 5697-5707.	7.0	200
139	Immunotherapy of hepatocellular carcinoma. Hepatic Oncology, 2014, 1, 433-446.	4.2	5
140	Nonsurgical Treatment for Localized Hepatocellular Carcinoma. Current Oncology Reports, 2014, 16, 373.	4.0	13
141	Chemoembolization and radioembolization. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 909-919.	2.4	19
142	Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension. Hpb, 2014, 16, 243-249.	0.3	69
143	Prospective Randomized Trial of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid for Prevention of Radiation-Induced Liver Toxicity. PLoS ONE, 2014, 9, e112731.	2.5	46
144	Dosimetry and Dose Calculation. Medical Radiology, 2013, , 53-61.	0.1	1

#	ARTICLE	IF	CITATIONS
145	Trial of complete weaning from immunosuppression for liver transplant recipients: Factors predictive of tolerance. <i>Liver Transplantation</i> , 2013, 19, 937-944.	2.4	87
146	Reply to: "Pre-therapeutic dosimetry evaluation and selective internal radiation therapy of hepatocellular carcinoma using yttrium-90-loaded microspheres". <i>Journal of Hepatology</i> , 2013, 58, 1056-1057.	3.7	4
147	Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 59, 753-761.	3.7	82
148	Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives. <i>Hepatology</i> , 2013, 58, 2188-2197.	7.3	154
149	Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: The Emerging Role for Radioembolization Using Yttrium-90. <i>Oncology</i> , 2013, 84, 311-318.	1.9	134
150	Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model. <i>Clinical Cancer Research</i> , 2013, 19, 6151-6162.	7.0	92
151	A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. <i>Journal of Hepatology</i> , 2013, 59, 81-88.	3.7	816
152	Stakeholder perspectives on European priorities for comprehensive liver cancer control: a conjoint analysis. <i>European Journal of Public Health</i> , 2013, 23, 951-957.	0.3	4
153	Radioembolization-Induced Liver Disease. <i>Medical Radiology</i> , 2013, , 177-185.	0.1	0
154	Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 827-841.	4.1	5
155	Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions. <i>Seminars in Liver Disease</i> , 2013, 32, 348-359.	3.6	508
156	Surgical Treatment and Radioembolization. <i>Medical Radiology</i> , 2013, , 167-170.	0.1	0
157	Radioembolization: Concepts and Procedures. <i>Medical Radiology</i> , 2013, , 361-377.	0.1	0
158	Prognostic factors and prevention of radioembolization-induced liver disease. <i>Hepatology</i> , 2013, 57, 1078-1087.	7.3	240
159	Zolmitriptan: A Novel Portal Hypotensive Agent Which Synergizes with Propranolol in Lowering Portal Pressure. <i>PLoS ONE</i> , 2013, 8, e52683.	2.5	5
160	Results in Hepatocellular Carcinoma. <i>Medical Radiology</i> , 2013, , 105-117.	0.1	2
161	Long-term follow-up study of gastroduodenal lesions after radioembolization of hepatic tumors. <i>World Journal of Gastroenterology</i> , 2013, 19, 2935-2940.	3.3	22
162	Radioembolization for the Treatment of Liver Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 91-99.	1.3	118

#	ARTICLE	IF	CITATIONS
163	Integrating Radioembolization With Chemotherapy in the Treatment Paradigm for Unresectable Colorectal Liver Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 293-301.	1.3	21
164	Integrating Radioembolization (90Y Microspheres) Into Current Treatment Options for Liver Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 81-90.	1.3	22
165	Radioembolization in the Treatment of Unresectable Liver Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 167-177.	1.3	40
166	Integrating Radioembolization into the Treatment Paradigm for Metastatic Neuroendocrine Tumors in the Liver. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 393-398.	1.3	31
167	Radioembolization for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 464-473.	3.7	268
168	The ENRY analysis: a 325-patient European multicentre analysis. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 23-26.	2.2	2
169	Patient selection criteria for selective internal radiation therapy and integration into treatment guidelines. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 76-80.	2.2	1
170	Patient Selection and Activity Planning Guide for Selective Internal Radiotherapy With Yttrium-90 Resin Microspheres. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 401-407.	0.8	190
171	Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. <i>Liver Transplantation</i> , 2012, 18, 45-52.	2.4	143
172	Research Reporting Standards for Radioembolization of Hepatic Malignancies. <i>Journal of Vascular and Interventional Radiology</i> , 2011, 22, 265-278.	0.5	185
173	Treatment of murine fulminant hepatitis with genetically engineered endothelial progenitor cells. <i>Journal of Hepatology</i> , 2011, 55, 828-837.	3.7	14
174	Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection. <i>Journal of Hepatology</i> , 2011, 54, 422-431.	3.7	68
175	Radioembolization for Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 422-431.	1.3	91
176	General Selection Criteria of Patients for Radioembolization of Liver Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 337-341.	1.3	72
177	Prognosis of Hepatocellular Carcinoma in Relation to Treatment Across BCLC Stages. <i>Annals of Surgical Oncology</i> , 2011, 18, 1964-1971.	1.5	53
178	A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma. <i>Functional and Integrative Genomics</i> , 2011, 11, 419-429.	3.5	19
179	Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: The effect of smoking withdrawal. <i>Liver Transplantation</i> , 2011, 17, 402-408.	2.4	89
180	Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. <i>Hepatology</i> , 2011, 54, 868-878.	7.3	550

#	ARTICLE	IF	CITATIONS
181	Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2011, 129, 374-386.	5.1	16
182	In Reply to Dr. Kao et al.. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1280-1281.	0.8	1
183	Transarterial therapies for hepatocellular carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1057-1073.	1.8	32
184	Pilot Clinical Trial of Type 1 Dendritic Cells Loaded with Autologous Tumor Lysates Combined with GM-CSF, Pegylated IFN, and Cyclophosphamide for Metastatic Cancer Patients. <i>Journal of Immunology</i> , 2011, 187, 6130-6142.	0.8	59
185	Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 391-398.	1.6	60
186	Safety and Efficacy Assessment of Flow Redistribution by Occlusion of Intrahepatic Vessels Prior to Radioembolization in the Treatment of Liver Tumors. <i>CardioVascular and Interventional Radiology</i> , 2010, 33, 523-531.	2.0	56
187	Analysis of Prognostic Factors After Yttrium-90 Radioembolization of Advanced Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1441-1448.	0.8	54
188	A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. <i>Cancer Gene Therapy</i> , 2010, 17, 837-843.	4.6	103
189	Liver Radioembolization Using ⁹⁰ Y Resin Microspheres in Elderly Patients: Tolerance and Outcome. <i>Hospital Practice (1995)</i> , 2010, 38, 103-109.	1.0	8
190	Radioembolization with Use of Yttrium-90 Resin Microspheres in Patients with Hepatocellular Carcinoma and Portal Vein Thrombosis. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 1205-1212.	0.5	136
191	Gene therapy for liver cancer: clinical experience and future prospects. <i>Current Opinion in Molecular Therapeutics</i> , 2010, 12, 561-9.	2.8	12
192	Wilms' Tumor 1 Gene Expression in Hepatocellular Carcinoma Promotes Cell Dedifferentiation and Resistance to Chemotherapy. <i>Cancer Research</i> , 2009, 69, 1358-1367.	0.9	46
193	Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?. <i>Immunotherapy</i> , 2009, 1, 845-853.	2.0	17
194	Spontaneous Regression of Hepatocellular Carcinoma: Three Case Reports and a Categorized Review of the Literature. <i>Digestive Diseases and Sciences</i> , 2009, 54, 1147-1153.	2.3	47
195	Biocompatibility, Inflammatory Response, and Recanalization Characteristics of Nonradioactive Resin Microspheres: Histological Findings. <i>CardioVascular and Interventional Radiology</i> , 2009, 32, 727-736.	2.0	74
196	Usefulness of a program of neoplasia surveillance in liver transplantation. A preliminary report. <i>Clinical Transplantation</i> , 2009, 23, 532-536.	1.6	51
197	Treatment Parameters and Outcome in 680 Treatments of Internal Radiation With Resin ⁹⁰ Y-Microspheres for Unresectable Hepatic Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1494-1500.	0.8	238
198	Treatment of Hepatocellular Carcinoma by Radioembolization Using ⁹⁰ Y Microspheres. <i>Digestive Diseases</i> , 2009, 27, 164-169.	1.9	30

#	ARTICLE	IF	CITATIONS
199	Spontaneous regression of hepatocellular carcinoma: a systematic review. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 254-257.	1.6	69
200	A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. <i>Hepato-Gastroenterology</i> , 2009, 56, 1683-8.	0.5	33
201	Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. <i>Liver Transplantation</i> , 2008, 14, 272-278.	2.4	128
202	Liver disease induced by radioembolization of liver tumors. <i>Cancer</i> , 2008, 112, 1538-1546.	4.1	330
203	Comparative Study of Four Different Spherical Embolic Particles in an Animal Model: A Morphologic and Histologic Evaluation. <i>Journal of Vascular and Interventional Radiology</i> , 2008, 19, 1625-1638.	0.5	58
204	Gastroduodenal Injury After Radioembolization of Hepatic Tumors. <i>American Journal of Gastroenterology</i> , 2007, 102, 1216-1220.	0.4	128
205	Pneumatosis coli due to pharmacological constipation. <i>Gastrointestinal Endoscopy</i> , 2007, 65, 710-711.	1.0	2
206	Gene therapy of liver cancer. <i>Annals of Hepatology</i> , 2007, 6, 5-14.	1.5	22
207	Gene therapy of liver cancer. <i>World Journal of Gastroenterology</i> , 2006, 12, 6085.	3.3	27
208	Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 792-800.	0.8	207
209	Future therapies for hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 515-521.	1.6	9
210	Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. <i>International Journal of Cancer</i> , 2005, 116, 275-281.	5.1	112
211	De Novo neoplasia after liver transplantation: An analysis of risk factors and influence on survival. <i>Liver Transplantation</i> , 2005, 11, 89-97.	2.4	139
212	Older age and liver transplantation. <i>Liver Transplantation</i> , 2005, 11, 119-119.	2.4	1
213	Nonmelanoma skin cancer after liver transplantation. Study of risk factors. <i>Liver Transplantation</i> , 2005, 11, 1100-1106.	2.4	82
214	Gene Therapy of Cancer Based on Interleukin 12. <i>Current Gene Therapy</i> , 2005, 5, 573-581.	2.0	85
215	Intratumoral Injection of Dendritic Cells Engineered to Secrete Interleukin-12 by Recombinant Adenovirus in Patients With Metastatic Gastrointestinal Carcinomas. <i>Journal of Clinical Oncology</i> , 2005, 23, 999-1010.	1.6	170
216	Refined tools for the treatment of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2005, 42, 629-631.	3.7	10

#	ARTICLE	IF	CITATIONS
217	Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: Results of a pilot randomized controlled clinical trial. <i>Journal of Hepatology</i> , 2005, 43, 630-636.	3.7	97
218	The Role of Thrombopoietin in the Thrombocytopenia of Patients with Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2005, 100, 1311-1316.	0.4	122
219	Positron Emission Tomography Imaging of Adenoviral-Mediated Transgene Expression in Liver Cancer Patients. <i>Gastroenterology</i> , 2005, 128, 1787-1795.	1.3	211
220	Phase I Trial of Intratumoral Injection of an Adenovirus Encoding Interleukin-12 for Advanced Digestive Tumors. <i>Journal of Clinical Oncology</i> , 2004, 22, 1389-1397.	1.6	295
221	Herpes zoster after liver transplantation: Incidence, risk factors, and complications. <i>Liver Transplantation</i> , 2004, 10, 1140-1143.	2.4	76
222	Prolonged and inducible transgene expression in the liver using gutless adenovirus: A potential therapy for liver cancer. <i>Gastroenterology</i> , 2004, 126, 278-289.	1.3	86
223	Gene therapy of liver diseases. <i>Expert Opinion on Biological Therapy</i> , 2004, 4, 1073-1091.	3.1	31
224	Biologic therapy of liver tumors. <i>Surgical Clinics of North America</i> , 2004, 84, 673-696.	1.5	7
225	Positron emission tomography and gene therapy: basic concepts and experimental approaches for gene expression imaging. <i>Molecular Imaging and Biology</i> , 2004, 6, 225-238.	2.6	28
226	Liver Transplant Recipients Older Than 60 Years Have Lower Survival and Higher Incidence of Malignancy. <i>American Journal of Transplantation</i> , 2003, 3, 1407-1412.	4.7	105
227	A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis. <i>Gastroenterology</i> , 2003, 124, 1037-1042.	1.3	183
228	Gene therapy of neoplastic liver diseases. <i>International Journal of Biochemistry and Cell Biology</i> , 2003, 35, 135-148.	2.8	17
229	Liver Failure Caused by Herpes Simplex Virus Thymidine Kinase Plus Ganciclovir Therapy Is Associated with Mitochondrial Dysfunction and Mitochondrial DNA Depletion. <i>Human Gene Therapy</i> , 2003, 14, 463-472.	2.7	40
230	New strategies to enhance gene therapy efficiency. <i>Gastroenterology</i> , 2002, 123, 639-642.	1.3	15
231	Tracing Transgene Expression in Cancer Gene Therapy a Requirement for Rational Progress in the Field. <i>Molecular Imaging and Biology</i> , 2002, 4, 27-33.	2.6	30
232	Efficacy and Toxicity of Intra-Arterial Cisplatin and Etoposide for Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2002, 62, 293-298.	1.9	31
233	Gene Therapy of Hepatocellular Carcinoma and Gastrointestinal Tumors. <i>Annals of the New York Academy of Sciences</i> , 2002, 963, 6-12.	3.8	17
234	Gene Therapy of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2001, 19, 324-332.	1.9	19

#	ARTICLE	IF	CITATIONS
235	Idiopathic adulthood ductopenia: long-term follow-up after liver transplantation. <i>Digestive Diseases and Sciences</i> , 2001, 46, 1420-1423.	2.3	15
236	Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. <i>Hepatology</i> , 2001, 33, 52-61.	7.3	139
237	Liver transplantation in cirrhotic patients with diabetes mellitus: Midterm results, survival, and adverse events. <i>Liver Transplantation</i> , 2001, 7, 226-233.	2.4	46
238	Prognostic model for early acute rejection after liver transplantation. <i>Liver Transplantation</i> , 2001, 7, 246-254.	2.4	31
239	Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. <i>Liver Transplantation</i> , 2001, 7, 631-636.	2.4	184
240	Hyperhomocysteinemia in Liver Transplant Recipients: Prevalence and Multivariate Analysis of Predisposing Factors. <i>Liver Transplantation</i> , 2000, 6, 614-618.	2.4	20
241	Liver Damage using Suicide Genes. <i>American Journal of Pathology</i> , 2000, 157, 549-559.	3.8	35
242	Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. <i>Liver Transplantation</i> , 1999, 5, 414-420.	1.8	107
243	Effectiveness of lamivudine in treatment of acute recurrent hepatitis B after liver transplantation. <i>Digestive Diseases and Sciences</i> , 1998, 43, 1186-1189.	2.3	10
244	Risk factors for recurrence of hepatitis C after liver transplantation. <i>Liver Transplantation</i> , 1998, 4, 265-270.	1.8	25
245	Prognosis of hepatocellular carcinoma in relation to treatment: A multivariate analysis of 178 patients from a single European institution. <i>Surgery</i> , 1998, 124, 575-583.	1.9	57
246	Gene Transfer and Therapy with Adenoviral Vector in Rats with Diethylnitrosamine-Induced Hepatocellular Carcinoma. <i>Human Gene Therapy</i> , 1997, 8, 349-358.	2.7	75
247	PARTIAL SPLENIC EMBOLIZATION IN THE TREATMENT OF THROMBOCYTOPENIA AFTER LIVER TRANSPLANTATION. <i>Transplantation</i> , 1997, 63, 482-484.	1.0	15
248	Plasma levels of substance p in liver cirrhosis: Relationship to the activation of vasopressor systems and urinary sodium excretion. <i>Hepatology</i> , 1995, 21, 35-40.	7.3	47
249	Renal Biopsy with Forceps through the Femoral Vein. <i>Journal of Vascular and Interventional Radiology</i> , 1995, 6, 641-645.	0.5	12
250	Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: Effect on clinical, renal, humoral, and hemodynamic parameters*1. <i>Hepatology</i> , 1995, 21, 986-994.	7.3	14
251	Transvenous Liver Biopsy in Patients with Cirrhosis with Use of the Femoral Venous Approach and a Flexible Forceps. <i>Journal of Vascular and Interventional Radiology</i> , 1994, 5, 460-462.	0.5	5
252	Partial splenic embolization for the treatment of hypersplenism in cirrhosis. <i>Hepatology</i> , 1993, 18, 309-314.	7.3	148

#	ARTICLE	IF	CITATIONS
253	Effectiveness of Aprotinin in Orthotopic Liver Transplantation. <i>Seminars in Thrombosis and Hemostasis</i> , 1993, 19, 292-296.	2.7	22
254	Splenic embolization prior to myelosuppressive treatment in hepatocarcinoma and active chronic hepatitis. <i>European Journal of Radiology</i> , 1992, 15, 211-214.	2.6	6
255	Hepatitis B and C viral infections in patients with hepatocellular carcinoma. <i>Hepatology</i> , 1992, 16, 637-641.	7.3	129
256	Laparotomic eventration or colonic prolapse after chemotherapy-induced emesis. <i>Journal of Surgical Oncology</i> , 1988, 37, 204-206.	1.7	2
257	Dynamics in Circulating γ -55Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC – A Substudy From the SORAMIC Trial. , 0, 1, .		0